Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new KIT gene mutation in thymic cancer and a promising response to imatinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2013

Lim Sung Hee, Lee Ji-Yun, Sun Jong-Mu, Kim Kyoung-Mee, Ahn Jin Seok, Ahn Myung-Ju, Park Keunchil

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides
Share to Imatinib Mesylate
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Thymus Neoplasms

Source

Identifiers

PMID: 24457249
DOI: 10.1097/JTO.0b013e31829d51bd

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new KIT gene mutation in thymic cancer and a promising response to imatinib.PMID 24457249Read ↗

KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions.Semantic proximity Read ↗

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.Semantic proximity Read ↗

Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic CarcinomasSemantic proximity Read ↗

De novo leukemic variant of mast cell leukemia with KIT D816V.Semantic proximity Read ↗

Novel mutations of KIT gene in two Korean patients: variegated shades of phenotypes in tyrosine kinase 1 domain.Semantic proximity Read ↗

Identification of novel mutations of TP53, ALK and RET gene in metastatic thymic squamous cell carcinoma and its therapeutic implication.Semantic proximity Read ↗

Kit Mutations: New Insights and Diagnostic Value.Semantic proximity Read ↗

KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting.Semantic proximity Read ↗

c-Kit Receptors as a Therapeutic Target in Cancer: Current InsightsSemantic proximity Read ↗

C-KIT mutation in thymic carcinomas.Semantic proximity Read ↗

When a thymic carcinoma "becomes" a GIST.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.